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Abstract
Introduction: Determination of gene-candidates’ profile expression responsible for fibrosis, immunosuppression, angiogenesis, and 
neoplasia processes in the pathogenesis of thyroid gland disease.
Material and methods: Sixty-three patients underwent thyroidectomy: 27 with non-toxic nodular goitre (NG), 22 with toxic nodular 
goitre (TNG), six with papillary cancer (PTC), and eight with Graves’ disease (GD). In thyroid tissues, transcriptional activity of TGFb1 
and its receptors TGFbRI, TGFbRII, and TGFbRIII genes were assessed using RT-qPCR (Reverse Transcriptase Quantitative Polymerase 
Chain Reaction). Molecular analysis was performed in tissues derived from GD and from the tumour centre (PTC, NG, TNG) and from 
peripheral parts of the removed lobe without histopathological lesions (tissue control). Control tissue for analysis performed in GD was 
an unchanged tissue derived from peripheral parts of the removed lobe of patients surgically treated for a single benign tumour. 
Results/Conclusions: Strict regulation observed among transcriptional activity of TGFb1 and their receptor TGFbRI-III genes in control 
tissues is disturbed in all pathological tissues – it is completely disturbed in PTC and GD, and partially in NG and TNG. Additionally, higher 
transcriptional activity of TGFb1 gene in PTC in comparison with benign tissues (NG, GD) and lower expression of mRNA TGFbRII (than 
in TNG, GD) and mRNA TGFbRIII than in all studied benign tissues (NG, TNG, GD) suggests a pathogenetic importance of this cytokine 
and its receptors in PTC development. In GD tissue, higher transcriptional activity of TGFbRII and TGFbRIII genes as compared to other 
pathological tissues was observed, indicating a participation of the receptors in the pathomechanism of autoimmune thyroid disease (AITD). 
TGFb1 blood concentrations do not reflect pathological processes taking place in thyroid gland. (Endokrynol Pol 2016; 67 (4): 375–382)
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Streszczenie
Wstęp: Wyznaczenie profilu ekspresji genów-kandydatów odpowiedzialnych za procesy włóknienia, immunosupresji, angiogenezy, 
nowotworzenia w patogenezie chorób gruczołu tarczowego. 
Materiał i metody: W grupie badanej było 63 chorych poddanych tyreoidektomii: 27 z wolem guzkowym nietoksycznym (NG), 22 z wolem 
guzkowym toksycznym (TNG), 6 z rakiem brodawkowatym (PTC), 8 z chorobą Gravesa-Basedowa (GD). W tkankach tarczycy oceniono 
ilościowo aktywność transkrypcyjną genów TGFb1 i jego receptorów TGFbRI, TGFbRII, TGFbRIII metodą RT-qPCR (ilościową reakcją 
łańcuchową polimerazy z udziałem odwrotnej transkryptazy). Analizę molekularną wykonano w tkankach pochodzących od GD 
i z centrum zmiany guzowatej (PTC, NG, TNG) oraz z obwodowych części usuniętego płata w których nie stwierdzono zmian histopa-
tologicznych (tkanka kontrolna). Tkankę kontrolną dla analizy wykonanej u chorych z GD stanowiła niezmieniona tkanka tarczycy 
pochodząca z obwodowych części usuniętego płata chorych operowanych z powodu pojedynczego łagodnego guza. 
Wyniki/Wnioski: Obserwowana ścisła regulacja pomiędzy aktywnością transkrypcyjną genów TGFb1 i jego receptorów TGFbRI-III 
w tkankach kontrolnych ulega zaburzeniu we wszystkich tkankach patologicznych – całkowitemu w PTC i GD, częściowemu w NG i TGN. 
Dodatkowo, większa aktywność transkrypcyjna TGFb1 w PTC w porównaniu do tkanek łagodnych (NG, GD) oraz mniejsza ekspresja 
mRNA TGFbRII (niż w TNG, GD) i mRNA TGFbRIII w porównaniu z łagodnymi tkankami (NG, TNG, GD) sugeruje patogenetyczne 
znaczenie tej cytokiny i jej receptorów w rozwoju PTC. W tkance GD, zwraca uwagę większa aktywność transkrypcyjna genów TGFbRII 
i TGFbRIII w porównaniu do innych tkanek patologicznych wskazując na udział tych receptorów w patomechanizmie autoimmuno-
logicznej choroby tarczycy (AITD). Stężenia TGFb1 we krwi nie odzwierciedlają procesów patologicznych zachodzących w gruczole 
tarczowym. (Endokrynol Pol 2016; 67 (4): 375–382)
Słowa kluczowe: TGF beta 1; transformujący czynnik wzrostu beta 1; tarczyca; wole guzkowe; rak brodawkowaty; choroba Gravesa-Basedowa 
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Introduction
TGFb1 is a multifunctional cytokine. However, there are 
three fundamental directions of its activities: I. it regu-
lates cell proliferation, growth, differentiation, and cells 
movement; II. has immunomodulatory effects; and III. 
has profibrogenic effects. TGFb1 action can be local and 
systemic [1, 2]. It is an endogenous factor controlling ap-
optosis in normal and pathological tissues and thereby 
is a factor controlling the balance between replication 
and cell death [1, 3]. Lack of TGFb1-dependent growth 
control may result in oncogenesis. In normal conditions, 
TGFb1 is a potent inhibitor of the growth of many cell 
types, including neoplastic [1, 4]. In the early stages of 
cancer development, its cells respond to antimitotic 
effect of TGFb1 [1, 5]. However, at the entry of tumour 
cells into the phase of uncontrollable growth, most of 
them lose sensitivity to the inhibitory effect of TGFb1. 
What is more, these cancer cells begin to secrete TGFb1 
themselves [1, 4]. The TGFb1-dependent immunosup-
pressive activity and stimulating angiogenesis [4–7] cre-
ates a microenvironment favourable to tumour growth 
and its metastasis [1, 5]. TGFb1 induces the death of the 
surrounding healthy cells and thus eliminates their ef-
fect designed to inhibit tumour growth [1, 3]. The results 
of clinical and experimental studies indicate that the 
molecular reasons for the lack of cell response to TGFb1 
during malignant transformation is caused by mutation 
in the TGFbRII receptor [8]. TGFb1 was immunosup-
pressive in patients with Graves’ disease. It inhibited 
the proliferation of peripheral blood mononuclear cells 
and of peripheral and thyroid-derived T-cell lines and 
clones in response to non-specific stimuli. It also sup-
pressed the recognition of thyroid epithelial cells by 
thyroid autoantigen specific T-cell clones. TGFb1 may 
exert a variety of down-regulatory influences in Graves’ 
disease. It may be of importance for the suppression of 
autoaggression in persons predisposed to autoimmun-
ity; it may be quantitatively overrun by immunostimu-
latory influences in the acute phase of the disease; and 
it may be important for the induction of remission in 
patients with Graves’ disease [9, 10]. Triiodothyronine, 
through binding to its nuclear receptors (TRs), is able to 
antagonise transcriptional activation by TGFb/SMAD. 
This antagonism involves reduced phosphorylation of 
SMADs. T3 reduces occupancy of SMAD-binding ele-
ments in response to TGFb, reducing histone acetylation 
and inhibiting transcription [11]. 
The principle of the study was the determination 
of gene-candidates’ profile expression responsible for 
immunosuppression, angiogenesis, neoplasia, and 
fibrosis processes in the pathogenesis of thyroid gland 
disease. The objective of the study was to investigate 
the transcriptional activity of TGFb1 and its receptor 
(TGFbRI, TGFbRII, TGFbRIII) genes in diseased thyroid 
tissue in conjunction with the assessment of TGFb1 
concentration in the blood. 
Material and methods
The research was approved by the Ethical Committee 
of the Medical University of Silesia and was carried out 
in 2002–2007. Studies were performed altogether on 63 
patients (48 females, 15 males, mean age: 42.3 years): 
in eight patients undergoing a near total thyroidec-
tomy due to hyperthyreosis in the course of Graves’ 
disease (GD) and in 55 patients undergoing subtotal 
or total thyroidectomy due to tuberous changes. In 
the latter group, patients were divided into groups in 
dependence on histopathological diagnosis of change in 
thyroid gland (neoplastic change, benign change) and 
on hormonal status: the group with papillary cancer 
(PTC) consisted of six patients, with non-toxic nodular 
goitre (NG) — 27 patients, and with toxic nodular goitre 
(TNG) — 22 patients. After thyroidectomy each thyroid 
specimen was immediately frozen in liquid nitrogen 
and stored at -800C until it was used for RNA extraction. 
Paraffin-embedded thyroid specimens were histologi-
cally evaluated. Molecular analysis was performed in 
thyroid tissue derived from patients with Graves’ 
disease (group GD) and in tissue derived from tumour 
centre (groups PTC, NG, TNG) and from peripheral 
parts of the removed lobe without histopathological 
lesions (tissue control — C). Control tissue (C) for 
analysis performed in GD was an unchanged thyroid 
tissue derived from peripheral parts of removed lobe of 
patients surgically treated for a single benign tumour. In 
study groups, blood was collected at four points during 
the day (at 7 am, 1 pm, 7 pm, and 1 am) to determine 
the presence of a possible circadian rhythm of TGFb1 
and the calculation of its Mean Daily Concentrations 
(MDC) in the blood. Obtained sera were stored at -80°C 
until testing. In all those examined, the current endo-
crinological status was defined on the basis of thyroid 
gland ultrasound (USG), fine-needle aspiration biopsy 
(FNAB), serum levels of TSH (thyrotropin), fT4 (free 
thyroxin), eventually fT3 (free triiodothyronine), TSH 
receptor antibodies (TRAb), and anti-thyroid peroxidase 
antibodies (TPOAb). The control group (H) for estima-
tion of TGFb1MDC consisted of 20 healthy volunteers 
age- and sex-matched to diseased groups. The creation 
of the control group of healthy people composed from 
women and men was preceded in our previous study 
by a comparative analysis of the point concentrations 
of TGFb1 in the blood of women (n = 31) and the con-
centrations of TGFb1 in the blood of men (n = 28) [10]. 
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Analysis in blood 
Serum levels of TGFb1 were measured by an enzyme-
linked immunosorbent assay (ELISA) method using 
Quantikine Immunoassay (R&D Systems, USA) kits. 
Tests were performed in the Department of Pathophysi-
ology and Endocrinology with a Universal Microplate 
Spectrophotometer – μQUANT (BIOTEK INC). The 
sensitivity of the method was < 7 pg/mL, intra-assay 
error and inter-assay error were, respectively, 4.9% 
and 10.3%. TRAb and TPOAb were estimated, respec-
tively, by a radioimmune assay (RIA) method and the 
ELISA method. Serum levels of TSH and free thyroid 
hormones were assayed immunoenzymatically (MEIA) 
by routine laboratory techniques.
Molecular analysis in tissue
The expression of mRNA TGFb1 system subunits 
(TGFb1 and its receptors TGFbRI, TGFbRII, TGFbRIII) 
in thyroid tissue specimens were evaluated by Reverse 
Transcriptase Quantitative Polymerase Chain Reaction 
(RT-qPCR) with GAPDH as an indirect marker of tissue 
integrity.
RNA extraction from tissue specimens
Total RNA was isolated from the specimens applying 
commercially available kits (Total RNA Prep Plus A&A 
Biotechnology; Poland) according to manufacturer’s 
instruction based on the modification of the method 
of Chomczynski and Sacchi [12]. Quality of extracts 
was checked electrophoretically using 0.8% agarose gel 
stained with ethidium bromide. The results were ana-
lysed and registered using gel documentation system 
1D Bas-Sys (Biotech-Fisher). In the case of RNA extracts 
contaminated by genomic DNA, the latter was removed 
by DNAase I (MBI Fermentas) according to the manu-
facturer’s instruction. The concentration of total RNA 
was determined by spectrophotometric measurement 
in 5-mL capillaries using a Gene Quant II RNA/DNA 
Calculator (Pharmacia Biotech) making an assumption 
that the result of 1 OD, measured in a 10-mm light path 
cuvette, is equivalent to the concentration of 40 mg/cm3 
RNA extract.
Design of specific primers and probes used 
in the RT-qPCR reaction
Based on the data previously published in the Internet 
database GenBank (http://www.ncbi.nlm.nih.gov/irx/ 
/genbank) describing mRNA sequences for  studied 
genes, we designed specific primers and probes for 
mRNA of these genes using the  computer program 
Primer Express TM Version 1.0 ABI PRISM (Table I). 
Both primers as well as the probe were synthesized 
in the Oligo IBB PAN (Poland). The TaqMan probe 
consists of an oligonucleotide with a 5´-reporter dye 
and a downstream, 3´-quencher dye. The fluorescent 
reporter dye, such as FAM (6-carboxy-fluorescein), is 
covalently linked to the 5´ end of the oligonucleotide. 
Each of the reporters is quenched by TAMRA (6-car-
boxy-tetramethyl-rhodamine), typically located at the 
3´ end. When the probe is intact, the proximity of the 
reporter dye to the quencher dye results in suppression 
of the reporter fluorescence. 
Table I. Primer/probe sequences and size of amplicons generated by real-time RT-qPCR assay
Tabela I. Zaprojektowane zestawy starterów i sond hybrydyzacyjnych wykorzystywane w reakcjach RT-qPCR
Primer/Probe Oligo sequence Location mRNA Size of amplimer 
(bp)
Gene Source  
of sequence
TGFb1F 5’-TgAACCggCCTTTCCTgCTTCTCATg-3’ 1602-1627
152 pz TGFb1 [13]TGFb1R 5’-gCggAAgTCAATgTACAgCTgCCgC-3’ 1729-1753
TGFb1S* 5’-FAM-CCgCTggAgAgggCCCAgCATCTgCAAAgC-TAMRA-3’ 1634-1663
TGFbRIF 5’-ACTggCAgCTgTCATTgCTggACCAg-3’ 451-476
201 pz
TGFb1  
receptor I  
(TGFbRI)
[14]TGFbRIR 5’-CCTgAgCCAgAACCTgACgTTgTCATATCA-3’ 622-651
TGFbRIS* 5’-FAM-TgCCACAACCgCACTgTCATTCACCATCgA-TAMRA-3’ 518-547
TGFbRIIF 5’-ggCTCAACCACCAgggCATCCAgAT-3 1846-1870
139 pz
TGFb1  
receptor II 
(TGFbRII)
[15]TGFbRIIR 5’-CTCCCCgAgAgCCTgTCCAgATgCT-3’ 1960-1984
TGFbRIIS* 5’-FAM ACCACgACCCAgAggCCCgTCTCACAgCCC-TAMRA-3 1900-1929
TGFbRIIIF 5’-ACCgTgATgggCATTgCgTTTgCA-3’ 2698-2721
173 pz
TGFb1  
receptor III 
(TGFbRIII)
[16]TGFbRIIIR 5’-gTgCTCTgCgTgCTgCCgATgCTgT-3’ 2846-2870
TGFbRIIIS* 5’-FAM AggAAggCAgCAAgTCCCCACCTCCCCgCC-TAMRA-3’ 2790-2819
*probe labelled fluorescent dye FAM (6-carboxyfluoresceine) -5’ end and TAMRA (6-carboxytetramethylrhodamine) -3’ end
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Number of mRNA copies calculation  
by use of RT-qPCR
Extracted total RNA was a matrix in one-step RT-qPCR 
reaction, performed by thermostable enzyme Tth. One-
step quantitative RT-PCR using Tth DNA Polymerase 
depending on the type of ion present in the reaction 
mixture, manganese and magnesium, acts as either 
reverse transcriptase or DNA polymerase, respectively. 
The 10-mL reaction mixture contained five units Tth 
DNA Polymerase (Epicentre, USA), 1x MasterAmp 
10X PCR Enhancer (Epicentre, USA), 200 mM each of 
dATP, dTTP, dGTP, dCTP, 3 mM MgCl2, 0.5 μM MnSO4, 
1 × TaqMan Buffer A (Applied Biosystems, USA), and 
under 100 ng total RNA. The optimum concentrations 
of probes and primers were determined — see Table II.
ABI PRISM™ 7700 (TaqMan) sequence detector pur-
chased from Applied Biosystems Co. was used to per-
form RT-qPCR reaction. RT-qPCR assay was performed 
in triplicate for each sample. Cycling conditions were 
as follows: one step at 60°C for 30 minutes, one step at 
95°C for 5 minutes, 50 cycles at 95°C for 30 seconds, and 
60°C for 1 minute and one step at 72°C for 10 minutes. 
The hybridisation probe was labelled with a reporter 
fluorescent dye (FAM) at the 5’ end and a quencher 
fluorescent dye (TAMRA) at the 3’ end. When this 
probe was placed in the PCR, the DNA polymerase that 
catalyses the PCR also cuts off any probe that specifi-
cally binds to template. The nucleolytic degradation of 
the hybridisation probe releases the quenching of FAM 
fluorescence emission. The higher the starting copy 
number of the mRNA target, the earlier the significant 
increase in fluorescence is observed.
Glyceraldehydre-3-phosphate dehydrogenase 
(GAPDH) was used as internal control in all individuals 
RT-qPCR for all samples. Gene expression of GAPDH 
was analysed using specific sequence primers and 
probe (Table III).
On the basis the standard curve of each analysis 
was drawn and then an ABI PRISM™ 7700 sequence 
detector calculated the number of mRNA copies of the 
examined gene in analysed samples. RT-PCR products 
were run on 6% polyacrylamide gels and visualised 
with silver salts. To further confirm the product identity, 
they were sequenced with a BigDye Terminator V2.0 
Cycle Sequencing Kit (Applied Biosystems, USA) using 
an automated sequencer (ABI PRISMTM 310 Genetic 
Analyzer, Applied Biosystems, USA). 
Statistical analysis 
Results were subjected to routine statistical analysis us-
ing the program Statistica, with significance level set at 
p < 0.05. For each quantitative parameter, basic statistical 
characteristics were made - mean, SD (standard devia-
tion), SEM (standard error of the mean), minimal and 
maximal value, median, quartiles 25% and 75%, and 
95% confidence interval. Chronobiological parameter 
estimation was performed using the cosinor method 
[Model: M+A*cos((Pi/12)*T+fi)]. Homogeneity of vari-
ance was checked by Fischer test. U Mann-Whitney’s 
non-parametric rank sum test was applied where ap-
propriate. For the assessment of intergroup correlations, 
a Spearman Rank Correlation test was used.
Results
Performing quantitative analysis of mRNA TGFb1 and 
its receptors TGFbRI-III in thyroid tissue obtained from 
patients with papillary cancer (PTC), non-toxic nodular 
goitre (NG), toxic nodular goitre (TG), and Graves’ 
Table II. The optimum concentrations of primers and probes 
generated by real-time RT-qPCR assay
Tabela II. Optymalne stężenia starterów i sond hybrydy­
zacyjnych wykorzystywane w reakcjach RT-qPCR
Gene Sense primer Antisense primer Probe
TGFb1 0.2 μM 0.9 μM 0.3 μM
TGFb1RI 0.2 μM 0.4 μM 0.3 μM
TGFb1RII 0.4 μM 0.9 μM 0.3 μM
TGFb1RIII 0.4 μM 0.9 μM 0.3 μM
GAPDH 0.3 μM 0.3 μM 0.2 μM
Table III. Primer/probe sequences and size of amplicons generated by real-time RT-qPCR assay
Tabela III. Zaprojektowane zestawy starterów i sond hybrydyzacyjnych wykorzystywane w reakcjach RT-qPCR
Primer/Probe Oligo sequence Location mRNA Size of amplimer 
(bp)
Gene Source  
of sequence
GAPDHF 5’-gAAggTgAAggTCggAgTC-3’ 1457-1474
226 GAPDH [17]GAPDHR 5’-gAAgATggTgATgggATTC-3’ 3393-3412
GAPDHS* 5’-CAAgCTTCCCgTTCTCAgCC-3’ 3364-3383
* probe labelled fluorescent dye FAM (6-carboxyfluoresceine) -5’ end i TAMRA (6-carboxytetramethylrhodamine) -3’ end
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Table IV. Correlation coefficients among transcriptional activity of TGFb1 and its receptor (TGFbRI, TGFbII, TGFbIII) genes 
in diseased thyroid tissue derived from patients with papillary cancer (PTC), non­toxic (NG), and toxic nodular goitre (TNG), 
Graves’ disease (GD), and in control tissue (C)
Tabela IV. Analiza korelacji pomiędzy aktywnością transkrypcyjną genów TGFb1 i jego receptorów (TGFbRI, TGFbII, TGFbIII) 
w tkankach tarczycy pochodzącej od pacjentów z rakiem brodawkowatym tarczycy (PTC), wolem guzkowym (NG), wolem 
guzkowym toksycznym (TNG), chorobą Gravesa­Basedowa (GD) oraz w tkance kontrolnej (C)
mRNA C PTC NG TNG GD
R p R p R p R p R p
TGFb1 & TGFbRI 0.6597 0.0008 –0.8061 0.0528 0.1820 0.3636 0.4095 0.0584 –0.1687 0.6897
TGFb & TGFbRII –0.5278 0.0116 0.0896 0.8660 –0.4121 0.0327 0.3481 0.1124 0.1078 0.7995
TGFb1 & TGFbRIII 0.4813 0.0233 0.2687 0.6067 0.3827 0.0488 0.2744 0.2166 0.2755 0.5091
TGFbRI & TGFbRII 0.6425 0.0013 0.3529 0.4926 0.4856 0.0102 0.2950 0.1827 –0.2395 0.5678
TGFbRI & TGFbRIII 0.6096 0.0026 –0.2353 0.6536 0.1592 0.4276 0.3613 0.0985 –0.2635 0.5284
TGFbRII & TGFbRIII 0.9240 0.0000 0.2941 0.5715 0.3121 0.1130 0.8832 0.0000 0.6429 0.0856
R — Spearman’s correlation coefficient; p — significance level
disease (GD) has shown no difference in expression of 
the TGFb1 system subunits between diseased and con-
trol tissues in all studied groups of patients (Table IV). 
However, strict regulation observed among transcrip-
tional activity of TGFb1 and their receptors TGFbRI-III 
genes in control tissues is disturbed in all pathological 
tissues — it is completely disturbed in PTC and GD, 
and partially in NG and TNG (Table IV). Additionally, 
higher transcriptional activity of TGFb1 gene in PTC 
tissue in comparison with benign tissue (NG, GD) and 
lower expression of mRNA TGFbRII (than in TNG, GD) 
and mRNA TGFbRIII than in all studied benign tissues 
(NG, TNG, GD) suggest pathogenetic importance of 
this cytokine and its receptors in PTC development. In 
GD tissue, higher transcriptional activity of TGFbRII 
and TGFbRIII genes as compared to other pathological 
tissues was observed indicating participation of the re-
ceptors in the pathomechanism of autoimmune thyroid 
disease (AITD) (Table V).
Substantially, we did not observe differences in se-
rum TGFb1 concentrations between the studied groups; 
only in TNG patients was the cytokine level slightly 
decreased as compared to healthy controls (Table VI). 
TGFb1 blood concentrations rather do not reflect the 
pathological processes taking place in thyroid gland, 
although in patients with TNG we noted a correlation 
between TGFb1 concentration in blood and mRNA 
TGFbRII expression in thyroid (Spearman’s correlation 
coefficient (R) = –0.4257; p = 0.0482), which probably 
indicates the participation of circulating TGFb1 in the 
phenomenon of the receptor downregulation. No cir-
cadian rhythms of TGFb1 in all studied groups were 
found. No significant correlation was found between 
fT4, fT3, and measured TGFb1 system subunits expres-
sion. We also did not find any correlation between the 
TGFb1 system subunits expression and parameters of 
autoimmune thyroid disease, like TRAb or TPOAb.
Discussion
This study is the first report concerning the simultane-
ous quantitative analysis (RT-qPCR) of transcriptional 
activity of TGFb1 and its receptor (TGFbRI, TGFbRII, 
TGFbRIII) genes in thyroid tissue. The tissues derived 
from surgically treated patients with papillary can-
cer, nodular goitre (non-toxic and toxic), and Graves’ 
disease. In recent years, occasionally TGFb1 mRNA 
expression in thyroid tissue was estimated by RT-PCR 
[18]. Brace et al. (2014) demonstrated, using RT-qPCR, 
that expression of TGFb1 but not of TGFb2 is increased 
in papillary cancer tissue compared to benign nodule 
tissue [19]. Most reports describing TGFb1 in thyroid 
gland diseases are based on assay of this factor in blood 
[10] or on qualitative or semi-quantitative but not 
quantitative analysis of TGFb1 expression in thyroid 
tissue [20–23]. Immunohistochemical analyses of resec-
tion thyroid showed that the expressions of TGFb1 in 
thyroid cancers (papillary, follicular) were higher than 
in other benign thyroid lesions and normal thyroid tis-
sues. In the study nodular goitre and Graves’ disease 
tissues were also analysed [23]. The other immunohisto-
chemical studies examining the role of TGFb in human 
thyroid tissues revealed increased cytoplasmic presence 
of TGFb at the periphery of poorly circumscribed PTC. 
These tumours were associated with increased invasive-
ness and metastasis with an increased propensity to-
wards epithelial to mesenchymal transition [20, 21, 22]. 
In PTC cell lines and animal models, TGFb signalling 
has been shown to regulate cellular epithelial to mes-
enchymal transition [19, 20, 22, 25]. In thyroid PTC 
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cell lines, TGFb1 treatment was associated with the 
development more aggressive papillary cancer [24]. 
Overexpression of TGFb1 in thyroid tissue is associated 
with the occurrence of thyroid cancer, which can be 
used as a candidate for the diagnosis and prognosis of 
thyroid cancer [23].
In the tissues of thyroid cancers zero or reduced 
TGFbRII expression has been found compared to 
benign tumours and normal tissues [1, 26]. In the dif-
ferentiated and undifferentiated tissues of the thyroid 
cancers, resistance to TGFb1 coexisted with a reduction 
in mRNA and protein TGFbRII expression [1, 27]. TGFb1 
mRNA expression in PTC cells was higher compared to 
the surrounding tissues, while the TGFbRII was lower. 
An inverse correlation between TGFbRII and tumour 
size was found, and there was no such correlation 
with respect to TGFb1, which suggests that primarily 
TGFbRII plays a role in the pathogenesis of PTC [1, 28]. 
Metastatic thyroid cancer can also be characterised by 
a decreased sensitivity to the action of TGFb1 [29]. In 
human PTC, higher expression levels of TGFb1 were 
closely related with lymph node metastasis, whereas 
Smad3 expression increased significantly with ad-
vanced tumour stages. These findings suggest that the 
activation of TGFb/Smad3 pathways in cancer cells 
influences tumour growth [30]. The ability to inhibit 
tumour growth via TGFbRII, and the discovery of fac-
tors inducing the expression of this receptor in tumour 
cells, may be relevant to the treatment of malignant 
disease [1].
The application of molecular analysis of gene ex-
pression to clinical tissue samples represents one of 
the most exciting new areas in “translational” thyroid 
cancer research. Current data suggest that molecular 
diagnostic assays may improve the sensitivity and ac-
curacy of FNAB of thyroid nodules and lesions, metas-
tases, and detection of recurrent disease in peripheral 
blood samples [31]. Specified mRNA’s TGFb1 system 
expression and interactions among the system subunits 
identified in neoplastic tumour different than in other 
tissues may be considered in the context of improving 
PTC diagnostics. On the one hand, thyroid nodules and 
lesions being one of the commonest clinical situations 
rarely prove to be malignant, and on the other hand 
the diagnostic accuracy of FNAB is limited. FNAB is 
a highly sensitive method in the differential diagnosis of 
thyroid nodules and lesions; however, a large percent-
age of thyroid FNABs give a considerable proportion 
of non-diagnostic results, so there is a need to find new 
tools for more precise preoperative assessment [32–37]. 
Patients would benefit from improved preoperative 
diagnosis, which could reduce the number or extent 
of surgeries, long-term health costs, and postsurgical 
complications.
Molecular analysis of gene expression based on RT-
-qPCR represents new exciting areas of pathophysiol-
ogy because it creates the opportunity to explore the 
pathomechanisms occurring in the thyroid gland.
Conclusions
1. Strict regulation observed among transcriptional ac-
tivity of TGFb1 and their receptor TGFbRI-III genes 
in control tissues is disturbed in all pathological tis-
sues — it is completely disturbed in papillary cancer 
and Graves’ disease, and partially in non-toxic and 
toxic nodular goitre. 
2. In papillary cancer tissue, higher transcriptional 
activity of TGFb1 gene and lower transcriptional 
activity of TGFbRII and TGFbRIII genes in com-
parison with benign tissues suggests pathogenetic 
importance of this cytokine and its receptors in 
cancer development.
3. In Graves’ disease tissue, higher transcriptional ac-
tivity of TGFbRII and TGFbRIII genes in comparison 
with other pathological tissues indicates a partici-
Table VI. Mean Daily Concentrations (MDC) of TGFb1 in 
blood of patients with papillary cancer (PTC), non­toxic (NG) 
and toxic nodular goitre (TNG), Graves’ disease (GD), and in 
healthy controls (H)
Tabela VI. Porównanie średnich dobowych stężeń (MDC) 
dla TGFb1 we krwi chorych z rakiem brodawkowatym 
tarczycy (PTC), wolem guzkowym (NG), wolem guzkowym 
toksycznym (TNG), chorobą Gravesa­Basedowa (GD) 
i w grupie kontrolnej zdrowych (H)
Groups TGFb1 [ng/mL] 
MDC ±SD; ±SEM
PTC 38.34 ± 7.8; ± 3.2
NG 34.39 ± 6.8; ± 1.3
TNG 31.69 ± 6.0; ± 1.28
GD 40.08 ± 11.7; ± 4.12
H 38.2 ± 10.9; ± 1.16
Comparison between groups
PTC vs. H p = 0.734
NG vs. H p = 0.096
TNG vs. H p = 0.004
GD vs. H p = 0.624
PTC vs. NG p = 0.305
PTC vs. NTG p = 0.050
PTC vs. GD p = 0.606
NG vs. TNG p = 0.228
TNG vs. GD p = 0.067
NG vs. GD p = 0.223
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pation of the receptors in the pathomechanism of 
autoimmune thyroid disease (AITD).
4. TGFb1 blood concentrations rather do not reflect 
pathological processes taking place in thyroid gland, 
although in patients with toxic nodular goitre we 
noted a correlation between TGFb1 concentration 
in blood and mRNA TGFbRII expression in thyroid, 
which probably indicates the participation of circu-
lating TGFb1 in the phenomenon of the receptor 
downregulation.
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